For release: 14 February 2018
genedrive plc ("genedrive" or the "Company")
Notice of Interim Results
genedrive plc, (AIM: GDR), the near patient molecular diagnostics company, will be announcing its interim results for the six months ending 31 December 2017 on Tuesday 20 March.
David Budd, Chief Executive Officer, and Matthew Fowler, Chief Financial Officer, will host a presentation and simultaneous live conference call for analysts, followed by a Q&A session, at 9:30am on the day of the results. The presentation will be held at 85 Gresham Street, London, EC2R 7HE.
- Ends -
For further details please contact:
David Budd: CEO +44 (0)161 989 0245
Matthew Fowler: CFO
Peel Hunt LLP
James Steel +44 (0)207 418 8900
Consilium Strategic Communications
Chris Gardner +44 (0)203 709 5700
Notes to Editors
About genedrive plc
genedrive plc is a molecular diagnostics company developing and commercialising a low cost, rapid, versatile, simple to use and robust point of need molecular diagnostics platform for the diagnosis of infectious diseases and for use in patient stratification (genotyping), pathogen detection and other indications. The Genedrive® platform and MTB/RIF assay has been launched in India and a Genedrive® HCV test has received CE-IVD Certification and has been launched in Africa. genedrive has distribution agreements with subsidiaries of Sysmex Corporation for the distribution of the Genedrive® platform in the EMEA and Asia Pacific regions .
This information is provided by RNS